Catalyst Wire Dossier Catalyst Wire Dossier

KVD001

· KalVista Pharmaceuticals, Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for KVD001, covering 2017-03-03 to 2020-12-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME) [Phase 2]

See pricing